Contact Us

At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.

Jeff Jensen

WEBINAR - 4 WAYS TO IMPLEMENT NGS LIQUID BIOPSIES- WITHOUT UMI

Our CTO, Dr. Cristian Ionescu-Zanetti, presented this webinar on Thursday, August 1. The webinar...

FLUXION BIOSCIENCES JOINS BLOODPAC CONSORTIUM TO ACCELERATE LIQUID BIOPSY DEVELOPMENT

Participation will help advance liquid biopsy adoption by collaborating among key industry...

GLYCOCALYX RESEARCH ACCELERATES WITH THE BIOFLUX SYSTEM

Glycocalyx research utilizing the BioFlux System

RECENT PUBLICATIONS VALIDATE FLUXION'S LIQUID BIOPSY TECHNOLOGIES

Publications demonstrate depth and breadth of Fluxion’s liquid biopsy technologies

FLUXION BIOSCIENCES RECEIVES NATIONAL CANCER INSTITUTE GRANT FOR DEVELOPMENT OF ERASE-SEQ LIQUID BIOPSY TECHNOLOGY

Grant will support advanced development and clinical validation with researchers at Cleveland Clinic

FLUXION BIOSCIENCES LAUNCHES CUSTOM LIQUID BIOPSY NGS PANEL DEVELOPMENT

Custom panels can be now be validated and analyzed using ERASE-Seq variant caller

NEW DATA DEMONSTRATES SUPERIOR ACCURACY OF FLUXION’S ERASE-SEQ VARIANT CALLER FOR LIQUID BIOPSIES

Inter-sample digital processing improves sensitivity and specificity of variant calling; results...